The magic of the hypoxia-signaling cascade

Cellular and Molecular Life Sciences

Volumn 65, Issue 7-8, 2008, Pages 1133-1149

  Benizri, E ^a   Ginouves A ^a   Berra, E ^b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CIC BIOGUNE   (Spain)

Author keywords

HIF signaling; Hypoxia; Oxygen homeostasis; Physiopathology; Therapy

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 [2 [4 (4,4' DIFLUOROBENZHYDRYLIDENE)PIPERIDINO]ETHYL] 2,3 DIHYDRO 2 THIOXO 4(1H) QUINAZOLINONE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ANTINEOPLASTIC AGENT; ARC 111; CARBOGEN; CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; ECHINOMYCIN; ERYTHROPOIETIN; FLUOROURACIL; GL 331; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; NICOTINAMIDE; OXYGEN; PACLITAXEL; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; QUINONE DERIVATIVE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RILUZOLE; TEMSIROLIMUS; TIRAPAZAMINE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; ANTISENSE THERAPY; CANCER INVASION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DEGRADATION; DRUG SCREENING; DRUG TARGETING; EMBRYO DEVELOPMENT; GENE THERAPY; HOMEOSTASIS; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; INFLAMMATION; ISCHEMIA; ISCHEMIC HEART DISEASE; LUNG NON SMALL CELL CANCER; METABOLISM; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PERINATAL PERIOD; PREECLAMPSIA; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; RNA INTERFERENCE; SENSITIZATION; SUICIDE GENE THERAPY; SURVIVAL; TUMOR GROWTH; WOUND HEALING;

ANIMALS; ANOXIA; CARDIOVASCULAR DISEASES; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 42449084992     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-7472-0     Document Type: Review

References (171)

1. Semenza, G. L. (2000) HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88, 1474-1480.
2. Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y. and Fujii-Kuriyama, Y. (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 94, 4273-4278.
3. Gu, Y. Z., Moran, S. M., Hogenesch, J. B., Wartman, L. and Bradfield, C. A. (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 7, 205-213.
4. Wang, G. L., Jiang, B. H., Rue, E. A. and Semenza, G. L. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514.
5. 2 sensing. Science 292, 464-468.
6. 2-regulated prolyl hydroxylation. Science 292, 468-472.
7. Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L. and Bruick, R. K. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471.
8. Mahon, P. C., Hirota, K. and Semenza, G. L. (2001) FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686.
9. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95, 7987-7992.
10. Salceda, S. and Caro, J. (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272, 22642-22647.
11. Kaelin, W. G. Jr. (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673-682.
12. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R. and Ratcliffe, P. J. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
13. Bruick, R. K. and McKnight, S. L. (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340.
14. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J. and Ratcliffe, P. J. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54.
15. Hirsila, M., Koivunen, P., Gunzler, V., Kivirikko, K. I. and Myllyharju, J. (2003) Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278, 30772-30780.
16. Berra, E., Ginouves, A. and Pouyssegur, J. (2006) The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signaling. EMBO Rep. 7, 41-45.
17. Cioffi, C. L., Liu, X. Q., Kosinski, P. A., Garay, M. and Bowen, B. R. (2003) Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem. Biophys. Res. Commun. 303, 947-953.
18. Lieb, M. E., Menzies, K., Moschella, M. C., Ni, R. and Taubman, M. B. (2002) Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem. Cell Biol. 80, 421-426.
19. Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J. H., Stolze, I., Klinger, M., Huang, W. Q., Wotzlaw, C., Hellwig-Burgel, T., Jelkmann, W., Acker, H. and Fandrey, J. (2003) Intracellular localisation of human HIF-1 alpha hydroxylases: Implications for oxygen sensing. J. Cell Sci. 116, 1319-1326.
20. Appelhoff, R. J., Tian, Y. M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J. and Gleadle, J. M. (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279, 38458-38465.
21. Berra, E., Benizri, E., Ginouves, A., Volmat, V., Roux, D. and Pouyssegur, J. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22, 4082-4090.
22. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732.
23. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W. and Nagy, A. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGFallele. Nature 380, 435-439.
24. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J. and Moore, M. W. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442.
25. Lin, C. S., Lim, S. K., D'Agati, V. and Costantini, F. (1996) Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 10, 154-164.
26. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D. and Keshert, E. (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490.
27. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12, 149-162.
28. Ryan, H. E., Lo, J. and Johnson, R. S. (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015.
29. Compernolle, V., Brusselmans, K., Acker, T., Hoet, P., Tjwa, M., Beck, H., Plaisance, S., Dor, Y., Keshet, E., Lupu, F., Nemery, B., Dewerchin, M., Van Veldhoven, P., Plate, K., Moons, L., Collen, D. and Carmeliet, P. (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8, 702-710.
30. Peng, J., Zhang, L., Drysdale, L. and Fong, G. H. (2000) The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc. Natl. Acad. Sci. USA 97, 8386-8391.
31. Scortegagna, M., Ding, K., Oktay, Y., Gaur, A., Thurmond, F., Yan, L. J., Marck, B. T., Matsumoto, A. M., Shelton, J. M., Richardson, J. A., Bennett, M. J. and Garcia, J. A. (2003) Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat. Genet. 35, 331-340.
32. Tian, H., Hammer, R. E., Matsumoto, A. M., Russell, D. W. and McKnight, S. L. (1998) The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12, 3320-3324.
33. Covello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C. J., Labosky, P. A., Simon, M. C. and Keith, B. (2006) HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20, 557-570.
34. Adelman, D. M., Gertsenstein, M., Nagy, A., Simon, M. C. and Maltepe, E. (2000) Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev. 14, 3191-203.
35. Maltepe, E. and Simon, M. C. (1998) Oxygen, genes, and development: An analysis of the role of hypoxic gene regulation during murine vascular development. J. Mol. Med. 76, 391-401.
36. Takeda, K., Ho, V. C., Takeda, H., Duan, L. J., Nagy, A. and Fong, G. H. (2006) Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol. 26, 8336-8346.
37. Palos, L. A. and Blasko, G. (1979) Effect of hypoxia on the development of Drosophila melanogaster (Meigen). Aviat. Space Environ. Med. 50, 411-412.
38. Datar, S. A., Jacobs, H. W., de la Cruz, A. F., Lehner, C. F. and Edgar, B. A. (2000) The Drosophila cyclin D-Cdk4 complex promotes cellular growth. EMBO J. 19, 4543-4554.
39. Frei, C. and Edgar, B. A. (2004) Drosophila cyclin D/Cdk4 requires Hif-1 prolyl hydroxylase to drive cell growth. Dev. Cell 6, 241-251.
40. Frei, C., Galloni, M., Hafen, E. and Edgar, B. A. (2005) The Drosophila mitochondrial ribosomal protein mRpL12 is required for Cyclin D/Cdk4-driven growth. EMBO J. 24, 623-634.
41. Centanin, L., Ratcliffe, P. J. and Wappner, P. (2005) Reversion of lethality and growth defects in Fatiga oxygen-sensor mutant flies by loss of hypoxia-inducible factor-alpha/Sima. EMBO Rep. 6, 1070-1075.
42. Goda, N., Ryan, H. E., Khadivi, B., McNulty, W., Rickert, R. C. and Johnson, R. S. (2003) Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23, 359-369.
43. Yun, Z., Lin, Q. and Giaccia, A. J. (2005) Adaptive myogenesis under hypoxia. Mol. Cell. Biol. 25, 3040-3055.
44. Yun, Z., Maecker, H. L., Johnson, R. S. and Giaccia, A. J. (2002) Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: A mechanism for regulation of adipogenesis by hypoxia. Dev. Cell 2, 331-341.
45. Morrison, S. J., Csete, M., Groves, A. K., Melega, W., Wold, B. and Anderson, D. J. (2000) Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. J. Neurosci. 20, 7370-7376.
46. Seagroves, T. N., Hadsell, D., McManaman, J., Palmer, C., Liao, D., McNulty, W., Welm, B., Wagner, K. U., Neville, M. and Johnson, R. S. (2003) HIF1alpha is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development 130, 1713-1724.
47. Gustafsson, M. V., Zheng, X., Pereira, T., Gradin, K., Jin, S., Lundkvist, J., Ruas, J. L., Poellinger, L., Lendahl, U. and Bondesson, M. (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617-628.
48. Diez, H., Fischer, A., Winkler, A., Hu, C. J., Hatzopoulos, A. K., Breier, G. and Gessler, M. (2007) Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp. Cell Res. 313, 1-9.
49. Tai, M. H., Chang, C. C., Kiupel, M., Webster, J. D., Olson, L. K. and Trosko, J. E. (2005) Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26, 495-502.
50. Kaidi, A., Williams, A. C. and Paraskeva, C. (2007) Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat. Cell Biol. 9, 210-217.
51. McMahon, S., Charbonneau, M., Grandmont, S., Richard, D. E. and Dubois, C. M. (2006) Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J. Biol. Chem. 281, 24171-24181.
52. Kong, T., Eltzschig, H. K., Karhausen, J., Colgan, S. P. and Shelley, C. S. (2004) Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. Proc. Natl. Acad. Sci. USA 101, 10440-10445.
53. Scannell, G., Waxman, K., Vaziri, N. D., Zhang, J., Kaupke, C. J., Jalali, M. and Hecht, C. C. (1995) Hypoxia-induced alterations of neutrophil membrane receptors. J. Surg. Res. 59, 141-145.
54. Mogford, J. E., Tawil, N., Chen, A., Gies, D., Xia, Y. and Mustoe, T. A. (2002) Effect of age and hypoxia on TGFbeta1 receptor expression and signal transduction in human dermal fibroblasts: Impact on cell migration. J. Cell Physiol. 190, 259-265.
55. O'Toole, E. A., Marinkovich, M. P., Peavey, C. L., Amieva, M. R., Furthmayr, H., Mustoe, T. A. and Woodley, D. T. (1997) Hypoxia increases human keratinocyte motility on connective tissue. J. Clin. Invest. 100, 2881-2891.
56. Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., Mukherjee, C., Shi, Y., Gelinas, C., Fan, Y., Nelson, D. A., Jin, S. and White, E. (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10, 51-64.
57. Saikumar, P., Dong, Z., Weinberg, J. M. and Venkatachalam, M. A. (1998) Mechanisms of cell death in hypoxia/reoxygenation injury. Oncogene 17, 3341-3349.
58. Bruick, R. K. (2000) Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA 97, 9082-9087.
59. Kothari, S., Cizeau, J., McMillan-Ward, E., Israels, S. J., Bailes, M., Ens, K., Kirshenbaum, L. A. and Gibson, S. B. (2003) BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22, 4734-4744.
60. Zhou, G., Golden, T., Aragon, I. V. and Honkanen, R. E. (2004) Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. J. Biol. Chem. 279, 46595-46605.
61. Santore, M. T., McClintock, D. S., Lee, V. Y., Budinger, G. R. and Chandel, N. S. (2002) Anoxia-induced apoptosis occurs through amitochondria-dependent pathway in lung epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L727-L734.
62. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M. E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241.
63. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M. and Donner, D. B. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82-85.
64. Dong, Z., Wang, J. Z., Yu, F. and Venkatachalam, M. A. (2003) Apoptosis-resistance of hypoxic cells: Multiple factors involved and a role for IAP-2. Am. J. Pathol. 163, 663-671.
65. Arnold, F., West, D. C., Schofield, P. F. and Kumar, S. (1987) Angiogenic activity in human wound fluid. Int. J. Microcirc. Clin. Exp. 5, 381-386.
66. Denko, N. C. and Giaccia, A. J. (2001) Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res. 61, 795-798.
67. Hockel, M. and Vaupel, P. (2001) Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266-276.
68. Mapp, P. I., Grootveld, M. C. and Blake, D. R. (1995) Hypoxia, oxidative stress and rheumatoid arthritis. Br. Med. Bull. 51, 419-436.
69. Cramer, T., Yamanishi, Y., Clausen, B. E., Forster, I., Pawlinski, R., Mackman, N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V., Firestein, G. S., Gerber, H. P., Ferrara, N. and Johnson, R. S. (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112, 645-657.
70. Hellwig-Burgel, T., Rutkowski, K., Metzen, E., Fandrey, J. and Jelkmann, W. (1999) Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 94, 1561-1567.
71. Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., Pouyssegur, J., Yaniv, M. and Mechta-Grigoriou, F. (2004) JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118, 781-794.
72. Cummins, E. P., Berra, E., Comerford, K. M., Ginouves, A., Fitzgerald, K. T., Seeballuck, F., Godson, C., Nielsen, J. E., Moynagh, P., Pouyssegur, J. and Taylor, C. T. (2006) Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc. Natl. Acad. Sci. USA 103, 18154-18159.
73. Tandara, A. A. and Mustoe, T. A. (2004) Oxygen in wound healing - More than a nutrient. World J. Surg. 28, 294-300.
74. Li, W., Li, Y., Guan, S., Fan, J., Cheng, C. F., Bright, A. M., Chinn, C., Chen, M. and Woodley, D. T. (2007) Extracellular heat shock protein-90alpha: Linking hypoxia to skin cell motility and wound healing. EMBO J. 26, 1221-1233.
75. Driscoll, M. and Gerstbrein, B. (2003) Dying for a cause: Invertebrate genetics takes on human neurodegeneration. Nat. Rev. Genet. 4, 181-194.
76. Brown, R. H. Jr. and Robberecht, W. (2001) Amyotrophic lateral sclerosis: Pathogenesis. Semin. Neurol. 21, 131-139.
77. Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Van Dorpe, J., Hellings, P., Gorselink, M., Heymans, S., Theilmeier, G., Dewerchin, M., Laudenbach, V., Vermylen, P., Raat, H., Acker, T., Vleminckx, V., VanDen Bosch, L., Cashman, N., Fujisawa, H., Drost, M. R., Sciot, R., Bruyninckx, F., Hicklin, D. J., Ince, C., Gressens, P., Lupu, F., Plate, K. H., Robberecht, W., Herbert, J. M., Collen, D. and Carmeliet, P. (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28, 131-138.
78. Subramanian, V. and Feng, Y. (2007) A new role for angiogenin in neurite growth and pathfinding: Implications for amyotrophic lateral sclerosis. Hum. Mol. Genet. 16, 1445-1453.
79. Selkoe, D. J., Yamazaki, T., Citron, M., Podlisny, M. B., Koo, E. H., Teplow, D. B. and Haass, C. (1996) The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann. N. Y. Acad. Sci. 777, 57-64.
80. Grammas, P., Samany, P. G. and Thirumangalakudi, L. (2006) Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J. Alzheimers Dis. 9, 51-58.
81. Shi, J., Yang, S. H., Stubley, L., Day, A. L. and Simpkins, J. W. (2000) Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model. Brain Res. 853, 1-4.
82. Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F. F., Xu, H. and Zhang, Y. W. (2007) Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J. Biol. Chem. 282, 10873-10880.
83. Wang, R., Zhang, Y. W., Zhang, X., Liu, R., Zhang, X., Hong, S., Xia, K., Xia, J., Zhang, Z. and Xu, H. (2006) Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia. FASEB J. 20, 1275-1277.
84. Genbacev, O., Zhou, Y., Ludlow, J. W. and Fisher, S. J. (1997) Regulation of human placental development by oxygen tension. Science 277, 1669-1672.
85. Caniggia, I., Mostachfi, H., Winter, J., Gassmann, M., Lye, S. J., Kuliszewski, M. and Post, M. (2000) Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3) J. Clin. Invest. 105, 577-587.
86. Vaupel, P. and Mayer, A. (2005) Hypoxia and anemia: Effects on tumor biology and treatment resistance. Transfus. Clin. Biol. 12, 5-10.
87. Vaupel, P., Thews, O. and Hoeckel, M. (2001) Treatment resistance of solid tumors: Role of hypoxia and anemia. Med. Oncol. 18, 243-259.
88. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L. and Simons, J. W. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59, 5830-5835.
89. Trastour, C., Benizri, E., Ettore, F., Ramaioli, A., Chamorey, E., Pouyssegur, J. and Berra, E. (2007) HIF-1alpha and CAIX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int. J. Cancer 120, 1451-1458.
90. Zhong, H., Semenza, G. L., Simons, J. W. and De Marzo, A. M. (2004) Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev. 28, 88-93.
91. Leek, R. D., Talks, K. L., Pezzella, F., Turley, H., Campo, L., Brown, N. S., Bicknell, R., Taylor, M., Gatter, K. C. and Harris, A. L. (2002) Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res. 62, 1326-1329.
92. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J. and Harris, A. L. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157, 411-421.
93. Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77 -85.
94. Kato, H., Inoue, T., Asanoma, K., Nishimura, C., Matsuda, T. and Wake, N. (2006) Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1. Int. J. Cancer 118, 1144-1153.
95. Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H. P., Johnson, R. S. and Bergers, G. (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146.
96. Thiery, J. P. (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15, 740-746.
97. Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q. T., Chi, J. T., Jeffrey, S. S. and Giaccia, A. J. (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226.
98. Imai, T., Horiuchi, A., Wang, C., Oka, K., Ohira, S., Nikaido, T. and Konishi, I. (2003) Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163, 1437-1447.
99. Peinado, H., DelCarmen Iglesias-de la Cruz, M., Olmeda, D., Csiszar, K., Fong, K. S., Vega, S., Nieto, M. A., Cano, A. and Portillo, F. (2005) A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 24, 3446-3458.
100. Shimoda, L. A., Fallon, M., Pisarcik, S., Wang, J. and Semenza, G. L. (2006) HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am. J. Physiol. Lung Cell Mol. Physiol. 291, L941-L949.
101. Ullah, M. S., Davies, A. J. and Halestrap, A. P. (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 281, 9030-9037.
102. Romero, M. F. (2005) Molecular pathophysiology of SLC4 bicarbonate transporters. Curr. Opin. Nephrol. Hypertens. 14, 495-501.
103. Wykoff, C. C., Beasley, N. J., Watson, P. H., Turner, K. J., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K. L., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J. and Harris, A. L. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60, 7075-7083.
104. Laderoute, K., Wardman, P. and Rauth, A. M. (1988) Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) Biochem. Pharmacol. 37, 1487-1495.
105. Weitman, S., Mangold, G., Marty, J., Dexter, D., Hilsenbeck, S., Rake, J., Juniewicz, P. and VonHoff, D. (1999) Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother. Pharmacol. 43, 402-408.
106. Wouters, B. G., Wang, L. H. and Brown, J. M. (1999) Tirapazamine: A new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann. Oncol. 10 Suppl 5, S29-S33.
107. Zeman, E. M., Hirst, V. K., Lemmon, M. J. and Brown, J. M. (1988) Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother. Oncol. 12, 209-218.
108. Williamson, S. K., Crowley, J. J., Lara, P. N., Jr., McCoy, J., Lau, D. H., Tucker, R. W., Mills, G. M. and Gandara, D. R. (2005) Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J. Clin. Oncol. 23, 9097-10104.
109. Rischin, D., Peters, L., Fisher, R., Macann, A., Denham, J., Poulsen, M., Jackson, M., Kenny, L., Penniment, M., Corry, J., Lamb, D. and McClure, B. (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98. 02). J. Clin. Oncol. 23, 79-87.
110. Theys, J., Landuyt, W., Nuyts, S., Van Mellaert, L., van Oosterom, A., Lambin, P. and Anne, J. (2001) Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 8, 294-297.
111. Kelleher, D. K., Matthiensen, U., Thews, O. and Vaupel, P. (1995) Tumor oxygenation in anemic rats: Effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol. 34, 379-384.
112. Silver, D. F. and Piver, M. S. (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer:Apossible oxygen effect. Gynecol. Oncol. 73, 280-284.
113. Stuben, G., Thews, O., Pottgen, C., Knuhmann, K., Vaupel, P. and Stuschke, M. (2001) Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J. Cancer Res. Clin. Oncol. 127, 346-350.
114. Harrison, L. B., Chadha, M., Hill, R. J., Hu, K. and Shasha, D. (2002) Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7, 492-508.
115. Feldmeier, J. J., Heimbach, R. D., Davolt, D. A., Brakora, M. J., Sheffield, P. J. and Porter, A. T. (1994) Does hyperbaric oxygen have a cancer-causing or-promoting effect? A review of the pertinent literature. Undersea Hyperb. Med. 21, 467-475.
116. Bennett, M., Feldmeier, J., Smee, R. and Milross, C. (2005) Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst. Rev. CD005007.
117. Kalns, J., Krock, L. and Piepmeier, E., Jr. (1998) The effect of hyperbaric oxygen on growth and chemosensitivity of metastatic prostate cancer. Anticancer Res. 18, 363-367.
118. Rojas, A. (1992) ARCON: Accelerated radiotherapy with carbogen and nicotinamide. BJR Suppl 24, 174-178.
119. Bernier, J., Denekamp, J., Rojas, A., Trovo, M., Horiot, J. C., Hamers, H., Antognoni, P., Dahl, O., Richaud, P., Kaanders, J., van Glabbeke, M. and Pierart, M. (1999) ARCON: Accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: A phase I/II study by the EORTC. Radiother. Oncol. 52, 149-156.
120. Hoskin, P. J., Rojas, A. M., Phillips, H. and Saunders, M. I. (2005) Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer 103, 2287-2297.
121. Grigsby, P. W., Winter, K., Wasserman, T. H., Marcial, V., Rotman, M., Cooper, J., Keys, H., Asbell, S. O. and Phillips, T. L. (1999) Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 80-05. Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 44, 513-517.
122. Overgaard, J., Sand Hansen, H., Lindelov, B., Overgaard, M., Jorgensen, K., Rasmusson, B. and Berthelsen, A. (1991) Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol. 20 Suppl 1, 143-149.
123. Huncharek, M. (1998) Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res. 18, 1935-1939.
124. Chen, J., Zhao, S., Nakada, K., Kuge, Y., Tamaki, N., Okada, F., Wang, J., Shindo, M., Higashino, F., Takeda, K., Asaka, M., Katoh, H., Sugiyama, T., Hosokawa, M. and Kobayashi, M. (2003) Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am. J. Pathol. 162, 1283-1291.
125. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G. and Powis, G. (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 3, 233-244.
126. Rapisarda, A., Uranchimeg, B., Scudiero, D. A., Selby, M., Sausville, E. A., Shoemaker, R. H. and Melillo, G. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316-4324.
127. Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H. and Melillo, G. (2004) Topoisomerase Imediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Res. 64, 1475-1482.
128. Meng, F., Nguyen, X. T., Cai, X., Duan, J., Matteucci, M. and Hart, C. P. (2007) ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation. Anticancer Drugs 18, 435-445.
129. Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H. and Melillo, G. (2005) Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65, 9047-9055.
130. Chang, A. Y., Kim, K., Boucher, H., Bonomi, P., Stewart, J. A., Karp, D. D. and Blum, R. H. (1998) A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: An Eastern Cooperative Oncology Group Study (E1587). Cancer 82, 292-300.
131. Muss, H. B., Blessing, J. A. and DuBeshter, B. (1993) Echinomycin in recurrent and metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group. Am. J. Clin. Oncol. 16, 492-493.
132. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G. and Livingston, D. M. (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6, 1335-1340.
133. D'Angelo, G., Duplan, E., Vigne, P. and Frelin, C. (2003) Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1alpha Pro-564 hydroxylation. J. Biol. Chem. 278, 15406-15411.
134. Temes, E., Martin-Puig, S., Acosta-Iborra, B., Castellanos, M. C., Feijoo-Cuaresma, M., Olmos, G., Aragones, J. and Landazuri, M. O. (2005) Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J. Biol. Chem. 280, 24238-24244.
135. Mayerhofer, M., Valent, P., Sperr, W. R., Griffin, J. D. and Sillaber, C. (2002) BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100, 3767-3775.
136. Wan, X., Shen, N., Mendoza, A., Khanna, C. and Helman, L. J. (2006) CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8, 394-401.
137. Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., Le, L., Oza, A., Nicklee, T., Ho, J., Birle, D., Pond, G. R., Arboine, D., Dancey, J., Aviel-Ronen, S., Tsao, M. S., Hedley, D. and Siu, L. L. (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 95, 1148-1154.
138. Hidalgo, M., Buckner, J. C., Erlichman, C., Pollack, M. S., Boni, J. P., Dukart, G., Marshall, B., Speicher, L., Moore, L. and Rowinsky, E. K. (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12, 5755-5763.
139. Hudis, C. A. (2007) Trastuzumab - Mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51.
140. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C. and Semenza, G. L. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004.
141. Yokoi, A., McCrudden, K. W., Huang, J., Kim, E. S., Soffer, S. Z., Frischer, J. S., Serur, A., New, T., Yuan, J., Mansukhani, M., O'Toole, K., Yamashiro, D. J. and Kandel, J. J. (2003) Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol. Rep. 10, 1271-1274.
142. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T. and Vogt, P. K. (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12, 363-369.
143. Sourbier, C., Lindner, V., Lang, H., Agouni, A., Schordan, E., Danilin, S., Rothhut, S., Jacqmin, D., Helwig, J. J. and Massfelder, T. (2006) The phosphoinositide 3-kinase/Akt pathway:Anew target in human renal cell carcinoma therapy. Cancer Res. 66, 5130-5142.
144. Richard, D. E., Berra, E., Gothie, E., Roux, D. and Pouyssegur, J. (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274, 32631-32637.
145. Chang, H., Shyu, K. G., Lee, C. C., Tsai, S. C., Wang, B. W., Hsien Lee, Y. and Lin, S. (2003) GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochem. Biophys. Res. Commun. 302, 95-100.
146. Tulis, D. A. (2004) Salutary properties of YC-1 in the cardiovascular and hematological systems. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2, 343-359.
147. Chun, Y. S., Yeo, E. J., Choi, E., Teng, C. M., Bae, J. M., Kim, M. S. and Park, J. W. (2001) Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. 61, 947-954.
148. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S. and Park, J. W. (2003) YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95, 516-525.
149. Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M., Remacle, J. and Michiels, C. (1999) Hypoxia-induced activation of HIF-1: Role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 460, 251-256.
150. Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simons, J. W. and Zhong, H. (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62, 2478-2482.
151. Hur, E., Kim, H. H., Choi, S. M., Kim, J. H., Yim, S., Kwon, H. J., Choi, Y., Kim, D. K., Lee, M. O. and Park, H. (2002) Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol. Pharmacol. 62, 975-982.
152. Sharp, S. and Workman, P. (2006) Inhibitors of the HSP90 molecular chaperone: Current status. Adv. Cancer Res. 95, 323-348.
153. Fotsis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P. and Schweigerer, L. (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368, 237-239.
154. Ricker, J. L., Chen, Z., Yang, X. P., Pribluda, V. S., Swartz, G. M. and Van Waes, C. (2004) 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin. Cancer Res. 10, 8665-8673.
155. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J. and Neckers, L. (2003) Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J. Biol. Chem. 278, 7445-7452.
156. Sun, X., Kanwar, J. R., Leung, E., Lehnert, K., Wang, D. and Krissansen, G. W. (2001) Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8, 638-645.
157. Sun, X., Liu, M., Wei, Y., Liu, F., Zhi, X., Xu, R. and Krissansen, G. W. (2006) Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Cancer Gene Ther. 13, 428-435.
158. Chang, Q., Qin, R., Huang, T., Gao, J. and Feng, Y. (2006) Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas 32, 297-305.
159. Binley, K., Askham, Z., Martin, L., Spearman, H., Day, D., Kingsman, S. and Naylor, S. (2003) Hypoxia-mediated tumour targeting. Gene Ther. 10, 540-549.
160. Mizuno, T., Nagao, M., Yamada, Y., Narikiyo, M., Ueno, M., Miyagishi, M., Taira, K. and Nakajima, Y. (2006) Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther. 13, 131-140.
161. Gillespie, D. L., Whang, K., Ragel, B. T., Flynn, J. R., Kelly, D. A. and Jensen, R. L. (2007) Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin. Cancer Res. 13, 2441-2448.
162. Li, J., Post, M., Volk, R., Gao, Y., Li, M., Metais, C., Sato, K., Tsai, J., Aird, W., Rosenberg, R. D., Hampton, T. G., Sellke, F., Carmeliet, P. and Simons, M. (2000) PR39, a peptide regulator of angiogenesis. Nat. Med. 6, 49-55.
163. Post, M. J., Sato, K., Murakami, M., Bao, J., Tirziu, D., Pearlman, J. D. and Simons, M. (2006) Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R494-R500.
164. Mabjeesh, N. J., Willard, M. T., Harris, W. B., Sun, H. Y., Wang, R., Zhong, H., Umbreit, J. N. and Simons, J. W. (2003) Dibenzoylmethane, a natural dietary compound, induces HIF-1 alpha and increases expression of VEGF. Biochem. Biophys. Res. Commun. 303, 279-286.
165. Natarajan, R., Salloum, F. N., Fisher, B. J., Ownby, E. D., Kukreja, R. C. and Fowler, A. A., 3rd. (2007) Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am. J. Physiol. Heart Circ. Physiol. 293, H1571-H1580.
166. Milkiewicz, M., Pugh, C. W. and Egginton, S. (2004) Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J. Physiol. 560, 21-26.
167. Warnecke, C., Griethe, W., Weidemann, A., Jurgensen, J. S., Willam, C., Bachmann, S., Ivashchenko, Y., Wagner, I., Frei, U., Wiesener, M. and Eckardt, K. U. (2003) Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J. 17, 1186-1188.
168. Vincent, K. A., Shyu, K. G., Luo, Y., Magner, M., Tio, R. A., Jiang, C., Goldberg, M. A., Akita, G. Y., Gregory, R. J. and Isner, J. M. (2000) Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 102, 2255-2261.
169. Rajagopalan, S., Olin, J., Deitcher, S., Pieczek, A., Laird, J., Grossman, P. M., Goldman, C. K., McEllin, K., Kelly, R. and Chronos, N. (2007) Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: Phase I dose-escalation experience. Circulation 115, 1234-1243.
170. Kelly, B. D., Hackett, S. F., Hirota, K., Oshima, Y., Cai, Z., Berg-Dixon, S., Rowan, A., Yan, Z., Campochiaro, P. A. and Semenza, G. L. (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93, 1074-1081.
171. Patel, T. H., Kimura, H., Weiss, C. R., Semenza, G. L. and Hofmann, L. V. (2005) Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc. Res. 68, 144-154.